Download PDF
Thromb Haemost 1999; 82(06): 1659-1662
DOI: 10.1055/s-0037-1614896
Rapid Communication
Schattauer GmbH

Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in situ in Laryngeal Carcinoma

Marek Z. Wojtukiewicz
1   From the Departments of Oncology, Medical Academy, Bialystok, Poland
,
Leo R. Zacharski
2   Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire and the Department of Veterans Affairs Medical and Regional Office Center, White River Junction, Vermont, USA
,
Monika Ruciñska
1   From the Departments of Oncology, Medical Academy, Bialystok, Poland
,
Lech Zimnoch
3   Pathological Anatomy, Medical Academy, Bialystok, Poland
,
Jacek Jaromin
4   Hematology and Medical Academy, Bialystok, Poland
,
Malgorzata Rózañska-Kudelska
5   Otolaryngology, Medical Academy, Bialystok, Poland
,
Walter Kisiel
6   Department of Pathology, University of New Mexico, School of Medicine, Albuquerque, New Mexico, USA
,
Bohdan J. Kudryk
7   Plasma Protein-Coagulation Laboratory, New York Blood Center, New York, USA
› Author AffiliationsThis work was supported, in part, by the Department of Veterans Affairs Medical Research Service.
Further Information

Publication History

Received 27 May 1999

Accepted after revision 24 August 1999

Publication Date:
10 December 2017 (online)

    Permissions and Reprints

Summary

The blood coagulation mechanism may support tumor progression by several mechanisms including promotion of cell proliferation and angiogenesis. Immunohistochemical procedures were applied to AMeX-fixed sections of twelve cases of squamous cell carcinoma of the larynx obtained at surgical resection to determine the presence and distribution of tissue factor (TF), tissue factor pathway inhibitor (TFPI), other coagulation factors, fibrinogen, and fibrin in situ. TF antigen was present in normal squamous epithelial cells and tumor cells, predominantly in immature tumor cells in the vicinity of the host-tumor interface. Tumor cells stained also for factors VII and X. Staining for TFPI antigen was demonstrated in the connective tissue stroma adjacent to the tumor, in microvascular endothelial cells, and in normal squamous epithelial cells. Fibrinogen and factor XIIIa were distributed throughout the tumor connective tissue stroma. Fibrin (thrombin-cleaved fibrinogen) was detected at the host-tumor interface and along the margins of tumor nodules. Tumor cells in carcinoma of the larynx express a functional, TF-initiated pathway of blood coagulation. Interpretation of these findings together with the results of clinical trials of inhibitors of TF-induced coagulation activation versus effects of inhibitors of TF expression suggest novel approaches to the experimental therapy of laryngeal carcinoma.

Keywords

Laryngeal carcinoma - tissue factor - angiogenesis - blood coagulation
 

  • References

  • 1 Camerer E, Kolsto A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
    CrossrefPubMedGoogle Scholar
  • 2 Osterud B, Rapaport S. Activation of factor IX by the reaction produced of tissue factor and factor VII. Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
    CrossrefPubMedGoogle Scholar
  • 3 Brose GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Res Med 1995; 46: 103-12.
    PubMedGoogle Scholar
  • 4 Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastas Rev 1992; 11: 249-66.
    PubMedGoogle Scholar
  • 5 Zacharski LR, Wojtukiewicz MZ, Constantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-16.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
    CrossrefPubMedGoogle Scholar
  • 7 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-49.
    CrossrefPubMedGoogle Scholar
  • 8 Lindahl AK, Sandset PM, Abildgaard U, Adersson TR, Harbitz TB. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989; 155: 389-93.
    PubMedGoogle Scholar
  • 9 Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SA. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Nasyrov VA, Osmonova RO, Rachkol AG. State of the hemostasis system in patients with malignant III-stage neoplasms of the maxilla and larynx. Vestn Otorinolaringol 1991; 5: 12-5.
    PubMedGoogle Scholar
  • 11 Nand S. Hemostasis and cancer. Cancer J 1993; 6: 54-8.
    PubMedGoogle Scholar
  • 12 Sato Y, Mukar K, Watanabe S, Goto M, Shimosato Y. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986; 125: 431-5.
    PubMedGoogle Scholar
  • 13 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-5.
    CrossrefPubMedGoogle Scholar
  • 14 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-58.
    PubMedGoogle Scholar
  • 15 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-21.
    CrossrefPubMedGoogle Scholar
  • 16 Kudryk B, Grossman ZD, Mcafee JG, Rosebrough SF. Monoclonal antibodies as probes for fibrin(ogen) proteolysis. In: Monoclonal antibodies in immunoscintigraphy. Chatal JF. ed. Boca Raton: CRC Press; 1989: 365-98.
    Google Scholar
  • 17 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21: 89-94.
    CrossrefPubMedGoogle Scholar
  • 18 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal fragments derived from fibrinogen and fibrin. Mol Immunol 1983; 20: 1191-200.
    CrossrefPubMedGoogle Scholar
  • 19 Mombelli G, Roux A, Haeberli A, Straub PW. Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381-8.
    PubMedGoogle Scholar
  • 20 Wojtukiewicz MZ, Zimnoch L, Jaromin J, Kloczko J, Bielawiec M, Matuszewska EA. Immunohistochemical demonstration of fibrin II in gastric cancer tissue. Pol J Pharmacol 1996; 48: 229-32.
    PubMedGoogle Scholar
  • 21 Dvorak HF, Harvey VS, Estrella P, Brown LF, Mc Donagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987; 57: 673-86.
    PubMedGoogle Scholar
  • 22 Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis 1988; 18: 37-46.
    PubMedGoogle Scholar
  • 23 Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA. et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993; 54: 793-80
    CrossrefPubMedGoogle Scholar
  • 24 Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased α11bβ3 expression on the cell surface. Thromb Res 1992; 68: 233-45.
    CrossrefPubMedGoogle Scholar
  • 25 Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993; 264: 1302-7.
    CrossrefPubMedGoogle Scholar
  • 26 Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 3: 379-84.
    CrossrefPubMedGoogle Scholar
  • 27 Kus J, Miodanski A, Olszewski E, Tyrankiewicz R. Morphology of arteries, veins, and capillaries in cancer of the larynx: scanning electron-microscopical study on microcorrision casts. J Cancer Res Clin Oncol 1981; 100: 271-83.
    CrossrefPubMedGoogle Scholar
  • 28 Murray JD, Carlson GW, McLaughlin K, Pennington M, Lynn M, DeRose PB. et al. Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am J Surg 1997; 174: 523-6.
    CrossrefPubMedGoogle Scholar
  • 29 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ. et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984; 53: 2046-52.
    CrossrefPubMedGoogle Scholar
  • 30 Zacharski LR, Morain WD, Schlaeppi J-M, Memoli VA, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissue by hirudin binding. Thromb Haemost 1995; 73: 793-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Barstad RM, Hamers MJ, Stephens RW, Sakariassen KS. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation. Blood 1995; 86: 212-8.
    PubMedGoogle Scholar
  • 32 Rashid J, weiss DJ, Maheswaran SK, Murtaugh MP. In vitro expression and inhibition of procoagulant activity produced by bovine alveolar macrophages and peripheral blood cells. Vet Res Commun 1996; 20: 519-31.
    CrossrefPubMedGoogle Scholar
  • 33 Saito T, Koyama T, Nagata K, Kamiyama R, Hirosawa S. Anticoagulant effect of retinoic acid on leukemia cells. Blood 1996; 87: 657-65.
    PubMedGoogle Scholar
  • 34 Khuri RF, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89: 199-211.
    CrossrefPubMedGoogle Scholar
  • 35 Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM. et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
    CrossrefPubMedGoogle Scholar
  • 36 Cooper MP, Klaassen I, Brakenhoff RH, Cloos J, Snow GB, Braakhuis BJ. All-transretinoic acid induced gene expression and growth inhibition in head and neck cancer cell lines. Oral Oncol 1997; 33: 270-4.
    CrossrefPubMedGoogle Scholar
  • 37 Allessandri C, Ferro D, Basili S, Vieri M, Cara D, Violi F. et al. Simvastation reduces enhanced monocyte tissue factor expression in patients with type IIa hypercholesterolemia. Thromb Haemost. 1997 206. (suppl 1) (abst S-833).
    PubMedGoogle Scholar
  • 38 Ollivier V, Ternisien C, Vu T, Hakim J, de Prost D. Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes. FEBS Lett 1993; 322: 231-4.
    CrossrefPubMedGoogle Scholar
  • 39 Holschermann H, Kohl O, Maus H, Tillmanns H, Haberbosch W. The effect of cyclosporine on monocyte tissue factor expression in cardiac transplant recipients. Thromb Haemost. 1997 206. (suppl 1) (abst S-835).
    PubMedGoogle Scholar
  • 40 Hamamoto T, Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1996; 7: 470-6.
    CrossrefPubMedGoogle Scholar
  • 41 Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
    Article in Thieme ConnectPubMedGoogle Scholar